SANOFI-ADR (SNY)

The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today

Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.

Why Is Auddia (AUUD) Stock Up 192% Today?

Auddia stock is taking off on Monday with heavy trading of AUUD stock after the company received a new AI tech patent.

AIRC Stock Alert: Blackstone Is Taking Apartment Income REIT Private

Apartment Income REIT stock is rising higher on Monday as investors in AIRC shares react to a deal to take the company private.

Sanofi Layoffs 2024: What to Know About the Latest SNY Job Cuts

Sanofi layoffs are coming for the company's R&D employees and it makes major changes to how it handles development going forward.

First Week of May 17th Options Trading For Sanofi (SNY)

First Week of September 20th Options Trading For Sanofi (SNY)

To the Moon and Beyond: 7 Stocks With Cosmic Potential

With the Fear and Greed Index at 69, it's an opportune to wager on these attractive Stocks with Moonshot Potential.

Passport to Profits: 7 Global Growth Gems to Diversify Your Holdings

With certain sectors in the domestic market appearing overstretched, these global growth stocks may offer better opportunities.

Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits

Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.

3 Cash Cow Dividend Stocks for Outsized Income & Upside

With uncertainty again weighing on the market, investors can take shelter under these cash cow dividend stocks.

Sanofi, Regeneron win FDA priority review for Dupixent label expansion (NASDAQ:SNY)

Sanofi and Regeneron's Dupixent receives priority review from FDA for its use in treating chronic obstructive pulmonary disease (COPD).

Move Over Magnificent 7, Say Hello to the GRANOLAS

Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods.

Regeneron, Vertex Pharma in $100B biotech club (NASDAQ:REGN)

Regeneron (REGN) and Vertex Pharmaceuticals (VRTX) join the $100B market cap club in the biotech industry, outperforming their rivals last year. Read more here.

Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests

The FDA put studies in eczema and asthma treatment on clinical hold.

Sanofi gains amid report of PE intersest in $20B consumer health unit

Sanofi's ADRs surge 3% as several prominent private equity firms express interest in its consumer health unit, per Bloomberg report.

Sanofi gains amid report of PE interest in $20B consumer health unit

Sanofi ADRs surge 3% as several prominent private equity firms express interest in its consumer health unit, per Bloomberg report.

2 Healthcare Stocks You Can Buy and Hold for the Next Decade

Don't count these companies out too soon.

Sanofi, Regeneron win Japan approval for Dupixent in CSU indication (NASDAQ:REGN)

Sanofi and Regeneron Pharmaceuticals gain approval for their allergy medication Dupixent in Japan, making it the first country to approve the drug for the...

7 Contrarian Biotech Stocks to Consider Amid Sector Weakness

Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts.

The 3 Biotech Stocks That Could Make Your February Unforgettable

After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.

AstraZeneca stock tumbles despite Q4 beat (NASDAQ:AZN)

AstraZeneca's operating profits fell short of expectations, but its oncology portfolio performed well, leading to a revenue beat in Q4 2023. Read more here.

Novo Nordisk To Up Production Capacity As Parent Buys Catalent

NVO stock rose after Novo Nordisk's parent, Novo Holdings, said it has agreed to buy contract manufacturer Catalent for $11.5 billion in cash.